Trials / Completed
CompletedNCT01145989
A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- NCIC Clinical Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the new drug AT9283 will slow the growth of multiple myeloma. Side effects of AT9283 will also be closely monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT9283 | Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks |
Timeline
- Start date
- 2011-02-15
- Primary completion
- 2014-10-29
- Completion
- 2015-11-27
- First posted
- 2010-06-17
- Last updated
- 2023-08-04
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01145989. Inclusion in this directory is not an endorsement.